Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
ADNOC Gas Targets Up to $4B Profit in 2026 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
MORRISTOWN, N.J., Feb. 22, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2017, after the market close on Thursday, March 8, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, March 8 | |
| Time: | 4:30 PM ET | |
| Toll free (U.S.): | 888-882-4478 | |
| International: | 323-794-2149 | |
| Conference ID: | 4931261 | |
| Webcast: | http://public.viavid.com/index.php?id=128364 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
